NCT01981499View on ClinicalTrials.gov

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

PHASE1TerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Migraine
Interventions
DRUG

PF-05180999

Ascending single oral doses of 120, 240, and 420 mg modified-release tablets

DRUG

Placebo

Placebo tablets

DRUG

120 mg MR PF-05180999

Single 120 mg dose administered as modified release formulation

DRUG

360 mg MR PF-05180999

Single 360 mg dose administered as modified release formulation

DRUG

10 mg cetirizine

Single 10 mg dose of cetirizine

DRUG

Placebo

Placebo tablets

Trial Locations (1)

55114

Pfizer Investigational Site, Saint Paul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01981499 - A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults | Biotech Hunter | Biotech Hunter